Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan Sells 546 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) CFO Timothy Eugene Sullivan sold 546 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $29.52, for a total value of $16,117.92. Following the completion of the sale, the chief financial officer now owns 128,665 shares in the company, valued at $3,798,190.80. This represents a 0.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Wednesday, January 22nd, Timothy Eugene Sullivan sold 3,088 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total value of $93,967.84.
• On Friday, January 17th, Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total value of $51,830.80.
• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Price Performance

Shares of APLS stock traded down $0.52 during trading hours on Monday, reaching $28.49. The company's stock had a trading volume of 1,501,925 shares, compared to its average volume of 1,930,394. The firm's 50 day simple moving average is $32.21 and its 200-day simple moving average is $32.76. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -14.03 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $24.34 and a fifty-two week high of $71.90. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.14). The business had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company's revenue for the quarter was up 78.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.17) EPS. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an "equal weight" rating and a $31.00 price objective on the stock. Citigroup lowered their target price on Apellis Pharmaceuticals from $63.00 to $51.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Scotiabank lowered their target price on Apellis Pharmaceuticals from $35.00 to $30.00 and set a "sector perform" rating on the stock in a research note on Wednesday, November 6th. Evercore ISI upgraded Apellis Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, October 31st. Finally, HC Wainwright reiterated a "buy" rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research note on Tuesday, January 14th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of large investors have recently modified their holdings of the business. KBC Group NV grew its stake in shares of Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company's stock valued at $76,000 after buying an additional 679 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company's stock valued at $130,000 after buying an additional 781 shares during the period. Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. True Wealth Design LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $27,000. Finally, Toronto Dominion Bank grew its stake in shares of Apellis Pharmaceuticals by 4.2% in the 3rd quarter. Toronto Dominion Bank now owns 25,622 shares of the company's stock valued at $739,000 after buying an additional 1,022 shares during the period. Institutional investors and hedge funds own 96.29% of the company's stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).